{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:28:56Z","timestamp":1792751336083,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T00:00:00Z","timestamp":1283817600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Visual hallucinations occur in various neurological diseases, but are most prominent in Lewy body dementia, Parkinson's disease and schizophrenia. The lifetime prevalence of visual hallucinations in patients with schizophrenia is much more common than conventionally thought and ranges from 24% to 72%. Cortical acetylcholine (ACh) depletion has been associated with visual hallucinations; the level of depletion being related directly to the severity of the symptoms. Current understanding of neurobiological visual processing and research in diseases with reduced cholinergic function, suggests that AChEI's may prove beneficial in treating visual hallucinations. This offers the potential for targeted drug therapy of clinically symptomatic visual hallucinations in patients with schizophrenia using acetylcholinesterase inhibition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A systematic review was carried out investigating the evidence for the effects of AChEI's in treating visual hallucinations in Schizophrenia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>No evidence was found relating to the specific role of AChEI's in treating visual hallucinations in this patient group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Given the use of AChEI's in targeted, symptom specific treatment in other neuropsychiatric disorders, it is surprising to find no related literature in schizophrenia patients. The use of AChEI's in schizophrenia has investigated effects on cognition primarily with non cognitive effects measured more broadly.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>We would suggest that more focused research into the effects of AChEI's on positive symptoms of schizophrenia, specifically visual hallucinations, is needed.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-244x-10-69","type":"journal-article","created":{"date-parts":[[2010,9,7]],"date-time":"2010-09-07T18:14:10Z","timestamp":1283883250000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Acetylcholinesterase Inhibitors (AChEI's) for the treatment of visual hallucinations in schizophrenia: A review of the literature"],"prefix":"10.1186","volume":"10","author":[{"given":"Sachin S","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizah","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhi","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,9,7]]},"reference":[{"key":"699_CR1","first-page":"46","volume":"146","author":"J Cummings","year":"1987","unstructured":"Cummings J, Miller B: Visual hallucinations: Clinical occurrence and use in differential diagnosis. West J Med. 1987, 146: 46-51.","journal-title":"West J Med"},{"key":"699_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1176\/ajp.146.4.526","volume":"146","author":"HS Bracha","year":"1989","unstructured":"Bracha HS, Wolkowitz OM, Karson CN, Bigelow LB: High prevalence of visual hallucinations in research subjects with chronic schizophrenia. Am J Psychiatry. 1989, 146: 526-528.","journal-title":"Am J Psychiatry"},{"key":"699_CR3","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev.psych.55.090902.142005","volume":"55","author":"D Kersten","year":"2004","unstructured":"Kersten D, Mamassian P, Yuille A: Object perception as bayesian inference. Annu Rev Psychology. 2004, 55: 271-304. 10.1146\/annurev.psych.55.090902.142005.","journal-title":"Annu Rev Psychology"},{"key":"699_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1098\/rstb.2005.1622","volume":"360","author":"K Friston","year":"2005","unstructured":"Friston K: A theory of cortical responses. Phil Trans R Soc B. 2005, 360: 815-836. 10.1098\/rstb.2005.1622.","journal-title":"Phil Trans R Soc B"},{"key":"699_CR5","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0893-6080(02)00058-8","volume":"15","author":"D Yu","year":"2002","unstructured":"Yu D, Dayan P: Acetylcholine in cortical inference. Neural Networks. 2002, 15: 719-730. 10.1016\/S0893-6080(02)00058-8.","journal-title":"Neural Networks"},{"issue":"6","key":"699_CR6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1017\/S0140525X05000130","volume":"28","author":"D Collerton","year":"2005","unstructured":"Collerton D, Perry E, McKeith I: Why people see things that are not there: A novel Perception and Attention Deficit model for recurrent complex visual hallucinations. Behavioral and Brain Sciences. 2005, 28 (6): 737-757.","journal-title":"Behavioral and Brain Sciences"},{"issue":"7","key":"699_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.4140\/TCP.n.2006.563","volume":"21","author":"AL Henriksen","year":"2006","unstructured":"Henriksen AL, St Dennis C, Setter SM, Tran JT: Dementia with lewy bodies: therapeutic opportunities and pitfalls. The Consultant Pharmacist. 2006, 21 (7): 563-75.","journal-title":"The Consultant Pharmacist"},{"issue":"6","key":"699_CR8","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000101512","volume":"23","author":"K Edwards","year":"2007","unstructured":"Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S: Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24 week open-label study. Dementia and Geriatric Cognitive Disorders. 2007, 23 (6): 401-5. 10.1159\/000101512.","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"1","key":"699_CR9","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s100720200022","volume":"23","author":"G Fabbrini","year":"2004","unstructured":"Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G: Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurological Sciences. 2004, 23 (1): 41-43. 10.1007\/s100720200022.","journal-title":"Neurological Sciences"},{"key":"699_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1176\/ajp.157.1.4","volume":"157","author":"JL Cummings","year":"2000","unstructured":"Cummings JL: Cholinesterase Inhibitors: A new Class of Psychotropic Compounds. Am J Psychiatry. 2000, 157: 1-4-15","journal-title":"Am J Psychiatry"},{"issue":"6","key":"699_CR11","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00023210-200013060-00001","volume":"13","author":"JL Cummings","year":"2000","unstructured":"Cummings JL, Askin-Edgar S: Evidence for Psychotropic Effects of Acetylcholinesterase Inhibitors. CNS Drugs. 2000, 13 (6): 385-395. 10.2165\/00023210-200013060-00001.","journal-title":"CNS Drugs"},{"issue":"5","key":"699_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1185\/030079902125000813","volume":"18","author":"R Bullock","year":"2002","unstructured":"Bullock R, Cameron A: Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Current Medical Research and Opinion. 2002, 18 (5): 258-64. 10.1185\/030079902125000813.","journal-title":"Current Medical Research and Opinion"},{"issue":"4","key":"699_CR13","doi-asserted-by":"publisher","first-page":"303","DOI":"10.2165\/11530260-000000000-00000","volume":"24","author":"SRI Ribeiz","year":"2010","unstructured":"Ribeiz SRI, Bassitt DP, Arrais JA, Avila R, Steffens DC, Bottino CMC: Cholinesterase Inhibitors as Adjunctive Therapy in Patients with Schizophrenia and Schizoaffective Disorder: A Review and Meta-Analysis of the Literature. CNS Drugs. 2010, 24 (4): 303-317. 10.2165\/11530260-000000000-00000.","journal-title":"CNS Drugs"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-10-69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-10-69\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-10-69","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-10-69.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:58:08Z","timestamp":1630468688000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-10-69"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["699"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-10-69","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,7]]},"assertion":[{"value":"20 February 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"69"}}